268 related articles for article (PubMed ID: 33670151)
1. Steroid-Resistant Graves' Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience.
Pérez-Moreiras JV; Varela-Agra M; Prada-Sánchez MC; Prada-Ramallal G
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33670151
[TBL] [Abstract][Full Text] [Related]
2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves' orbitopathy: an observational study.
Boutzios G; Chatzi S; Goules AV; Mina A; Charonis GC; Vlachoyiannopoulos PG; Tzioufas AG
Front Endocrinol (Lausanne); 2023; 14():1186105. PubMed ID: 37424868
[TBL] [Abstract][Full Text] [Related]
4. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease.
Toro-Tobon D; Rachmasari KN; Bradley EA; Wagner LH; Tooley AA; Stokken JK; Stan MN
Thyroid; 2023 Oct; 33(10):1237-1244. PubMed ID: 37515425
[No Abstract] [Full Text] [Related]
5. Tocilizumab versus Rituximab in Patients with Moderate to Severe Steroid-resistant Graves' Orbitopathy.
Bennedjaï A; Bouheraoua N; Gatfossé M; Dupasquier-Fediaevsky L; Errera MH; Tazartes M; Borderie V; Hennocq Q; Dellal A; Riviere S; Heron E; Fain O; Mekinian A
Ocul Immunol Inflamm; 2022 Feb; 30(2):500-505. PubMed ID: 32965148
[TBL] [Abstract][Full Text] [Related]
6. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with severity of orbitopathy in patients with Graves' disease.
Nabi T; Rafiq N
Taiwan J Ophthalmol; 2020; 10(3):197-202. PubMed ID: 33110751
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves' orbitopathy.
Park J; Kim J; Kim SS; Choi HY
Front Endocrinol (Lausanne); 2023; 14():1153312. PubMed ID: 37223049
[TBL] [Abstract][Full Text] [Related]
9. Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients.
Sánchez-Bilbao L; Martínez-López D; Revenga M; López-Vázquez Á; Valls-Pascual E; Atienza-Mateo B; Valls-Espinosa B; Maiz-Alonso O; Blanco A; Torre-Salaberri I; Rodríguez-Méndez V; García-Aparicio Á; Veroz-González R; Jovaní V; Peiteado D; Sánchez-Orgaz M; Tomero E; Toyos-Sáenz de Miera FJ; Pinillos V; Aurrecoechea E; Mora Á; Conesa A; Fernández-Prada M; Troyano JA; Calvo-Río V; Demetrio-Pablo R; González-Mazón Í; Hernández JL; Castañeda S; González-Gay MÁ; Blanco R
J Clin Med; 2020 Aug; 9(9):. PubMed ID: 32878150
[TBL] [Abstract][Full Text] [Related]
10. Antithymocyte Globulin as Second-Line Therapy in Graves Orbitopathy-Preliminary Results From a Prospective Single-Center Study.
Sarnat-Kucharczyk M; Świerkot M; Handzlik G; Kulawik G; Jagoda K; Grochoła-Małecka I; Fryżewska J; Mrukwa-Kominek E; Chudek J
Front Endocrinol (Lausanne); 2022; 13():871009. PubMed ID: 35615718
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial.
Perez-Moreiras JV; Gomez-Reino JJ; Maneiro JR; Perez-Pampin E; Romo Lopez A; Rodríguez Alvarez FM; Castillo Laguarta JM; Del Estad Cabello A; Gessa Sorroche M; España Gregori E; Sales-Sanz M;
Am J Ophthalmol; 2018 Nov; 195():181-190. PubMed ID: 30081019
[TBL] [Abstract][Full Text] [Related]
12. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
Woo YJ; Jang SY; Lim TH; Yoon JS
Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
[TBL] [Abstract][Full Text] [Related]
14. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
Lanzolla G; Sabini E; Leo M; Menconi F; Rocchi R; Sframeli A; Piaggi P; Nardi M; Marcocci C; Marinò M
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):733-742. PubMed ID: 34592164
[TBL] [Abstract][Full Text] [Related]
15. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
[TBL] [Abstract][Full Text] [Related]
16. Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience.
Sawicka-Gutaj N; Gruszczyński D; Zawalna N; Nijakowski K; Skiba A; Pochylski M; Sowiński J; Ruchała M
Pharmacol Rep; 2024 Feb; 76(1):185-194. PubMed ID: 38273183
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes in corticosteroid-refractory Graves' orbitopathy treated with tocilizumab.
Moi L; Hamedani M; Ribi C
Clin Endocrinol (Oxf); 2022 Sep; 97(3):363-370. PubMed ID: 34908176
[TBL] [Abstract][Full Text] [Related]
18. Risk Factors for Ocular Surface Irritation Symptoms in Inactive Mild and Moderate-to-Severe Graves' Orbitopathy.
Yu Y; Hu YX; Lu MX; Ouyang ZL; Xu MT; Zhao LY; Wang M
Ophthalmol Ther; 2024 Apr; 13(4):1015-1024. PubMed ID: 38376797
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate Mofetil (CellCept®) in Combination With Low Dose Prednisolone in Moderate to Severe Graves' Orbitopathy.
Rajabi MT; Rafizadeh SM; Mohammadi A; Eshraghi B; Mohammadi N; Hosseini SS; Rajabi MB; Keshmirshekan MM; Shahriari M; Poursayed Lazarjani SZ; Parandin MM
Front Med (Lausanne); 2022; 9():788228. PubMed ID: 35223896
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies for the treatment of Graves' ophthalmopathy: A systematic review and meta-analysis.
Fatani WA; Hamdan DM; Taher NO; Alsharef JF; Aldubi RM; Alwagdani AM; Alhothali TN; Khan ZU
Saudi J Ophthalmol; 2023; 37(2):137-148. PubMed ID: 37492211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
